Gerhard Krammer was born in Munich, Germany, in 1971. He received his M.S. degree in biology from Technical University of Munich, Munich, Germany in 1995. He has more than 13 years of experience in clinical drug development across several therapeutic areas. His main focus is efficacy, safety, and tolerability of drugs in arthritis/rheumatology (e.g., gouty arthritis, rheumatoid arthritis, and osteoarthritis) and other inflammatory or pain conditions, including pediatric and (ultra-) orphan development programs (e.g., systemic onset juvenile idiopathic arthritis, cryopyrin-associated periodic syndromes (MWS, FCAS/FCU, and NOMID/CINCA)). His drug development experience includes all stages of clinical development, from proof of concept/Phase I, and mostly from Phase II and III, to marketing authorization and Phase IV/postapproval studies. He is working as a program section leader in the pharmaceutical industry, currently for a development program of a fully human monoclonal antibody against interleukin 1-beta in difficult-to-treat gouty arthritis.
Biography Updated on 5 January 2011